



9381 Judicial Drive, Ste. 180  
San Diego, CA 92121  
Tel: 858.202.4900  
Fax: 858.450-6849

## **NEW U.S. PATENT GRANTED FOR NVENTA'S COVAL™ HPV FUSIONS TO TREAT PATIENTS WITH HPV-RELATED DISEASES**

**FOR IMMEDIATE RELEASE**

**October 29, 2007**

**San Diego, California USA** - Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today that the U.S. Patent and Trademark Office has issued Patent Number 7,262,014 to Nventa covering compositions and methods for inducing or enhancing immune responses to a human papillomavirus (HPV) antigen with or without the use of an adjuvant. The Company's CoVal™ HPV protein fusions are being developed to treat patients with HPV-related diseases.

This new U.S. patent provides for a method of treating a tumor expressing an HPV antigen through the administration of an effective amount of a composition comprised of an HPV antigen joined or fused to a stress protein. This patent provides additional patent exclusivity for HspE7, the Company's investigational therapeutic vaccine, and future HPV fusions through February 2019.

Gregory M. McKee, President and Chief Executive Officer at Nventa commented: "The issuance of this patent protecting the use of our HPV CoVal™ protein fusions to treat HPV-related diseases strengthens our intellectual property portfolio and, we believe, adds further value to our HspE7 program, which is currently in Phase 1 clinical development."

### **About Nventa Biopharmaceuticals Corporation:**

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at [www.nventacorp.com](http://www.nventacorp.com).

*This press release contains statements which, to the extent that they are not recitations of historical fact may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include financial and other projections as well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The*

words “may”, “would”, “could”, “will”, “likely”, “expect,” “anticipate,” “intend”, “plan”, “forecast”, “project”, “estimate” and “believe” or other similar words and phrases are intended to identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company’s actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning the coverage provided by this patent and our patent exclusivity for HspE7 and future HPV fusions.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, potential challenges to our patents, potential patent awards to third parties and other factors as described in detail in our filings with the Canadian securities regulatory authorities at [www.sedar.com](http://www.sedar.com). Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that challenges to our patents, if any, will be unsuccessful and that third parties will not obtain patents covering HPV fusions.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, including our 2006 Annual Information Form filed on SEDAR at <http://www.sedar.com>. Historical filings relating to the Company prior to the completion of the Company’s March 23, 2006 corporate reorganization, including Stressgen’s 2005 Annual Information Form dated March 16, 2006 may be reviewed on SEDAR at <http://www.sedar.com> under the SEDAR profile GVIC Publications Ltd.

All forward-looking statements and information made herein are based on our current expectations as of the date hereof and we disclaim any intention or obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Contact:

Donna Slade  
Director, Investor Relations  
9381 Judicial Drive, Suite 180  
San Diego, CA USA 92121  
Dir: 858.202.4945  
[dslade@nventacorp.com](mailto:dslade@nventacorp.com)